{"ticker": {"uuid": "f3476e31-5fc8-4ae8-bc65-e8c7b07e47d7", "symbol": "6628", "name": "Transcenta Holding Limited", "exchange": "HKG", "country": "HK", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Transcenta Returns Two Lilly-Licensed Compounds in US$4 Million Deal, Retains Blosozumab Rights", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxQdjgxYWl3M0s0YmFrZGJtNTl2MXQtQllRdTJ1Tk1VZXNoeEtVaEdUVVM4a21UUHdTVS1YT05kbGlDTUhMU2g4WGxWVkdSUHVHVl8tbmJkUmtrOFB6QVpieXhjelQzc1lHZVhHMUp1ZmxNN2otZV9YMVZjc2w4NDVMSE5TMWxlM0JjZ3N0azFEbEg3dk44QlV0OG43SnBxZkpPclJQWExoVFpwM2hfYUtCNm1vRWQ2aGJzc1h2NjVNYXVqMkxueXBycmxlcVZyMUp0SUZMMFY3MnFjU0RTUlE?oc=5", "source_name": "TipRanks", "published_at": "2026-07-07T11:41:03+00:00", "published_display": "07 Jul 2026 11:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Transcenta Holding Limited Announces Board and Committee Appointments", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOekhqaVNMZlFtUjROTHpOeWlfSm95QjBpakk5RDRxdEVtdWsyUGl1U1RWeDRBdHdjQ2h1MnM5UEs1RXVUXzdCT2RIWUtIQ1V3WF9lZUNVMTNXLTVXQXAxMzJUMm5vQXhyaC01Y1NCOG8xWG5EWDZETDZXcGd4QldwVk95SDR2T1JCV2lnR2RmMHA0eFZ2ZmhYdG5UY0FjVUdCVkJDS2htbTg5QVV3ZWFlUjROVkJxVmZvWk1ocE43Yw?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-30T12:25:00+00:00", "published_display": "30 Jun 2026 12:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Latham Advises the Underwriters in Transcenta\u2019s Hong Kong IPO", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxQLWNTeXNsSkQxazEwaFpfOENPbVlIT2xmalZqeUtNWWNTdDE3SzdxNC1TdGRUYnNmbjFZY0pBdHZIRmFCamlGVnQ1MWUzZmdUNUhhWVZxT1lqX1hGQVJhRlplYm1YcVRJOG5LaTBXdGd1YW52R2ZEYVlZcUYwQ1FNek1Xcl80Y3U3NW5z?oc=5", "source_name": "Latham & Watkins LLP", "published_at": "2021-09-29T07:00:00+00:00", "published_display": "29 Sep 2021 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Transcenta Returns Two Lilly-Licensed Compounds in US$4 Million Deal, Retains Blosozumab Rights", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxQdjgxYWl3M0s0YmFrZGJtNTl2MXQtQllRdTJ1Tk1VZXNoeEtVaEdUVVM4a21UUHdTVS1YT05kbGlDTUhMU2g4WGxWVkdSUHVHVl8tbmJkUmtrOFB6QVpieXhjelQzc1lHZVhHMUp1ZmxNN2otZV9YMVZjc2w4NDVMSE5TMWxlM0JjZ3N0azFEbEg3dk44QlV0OG43SnBxZkpPclJQWExoVFpwM2hfYUtCNm1vRWQ2aGJzc1h2NjVNYXVqMkxueXBycmxlcVZyMUp0SUZMMFY3MnFjU0RTUlE?oc=5", "source_name": "TipRanks", "published_at": "2026-07-07T11:41:03+00:00", "published_display": "07 Jul 2026 11:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Transcenta Holding Limited Announces Board and Committee Appointments", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOekhqaVNMZlFtUjROTHpOeWlfSm95QjBpakk5RDRxdEVtdWsyUGl1U1RWeDRBdHdjQ2h1MnM5UEs1RXVUXzdCT2RIWUtIQ1V3WF9lZUNVMTNXLTVXQXAxMzJUMm5vQXhyaC01Y1NCOG8xWG5EWDZETDZXcGd4QldwVk95SDR2T1JCV2lnR2RmMHA0eFZ2ZmhYdG5UY0FjVUdCVkJDS2htbTg5QVV3ZWFlUjROVkJxVmZvWk1ocE43Yw?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-30T12:25:00+00:00", "published_display": "30 Jun 2026 12:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Latham Advises the Underwriters in Transcenta\u2019s Hong Kong IPO", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxQLWNTeXNsSkQxazEwaFpfOENPbVlIT2xmalZqeUtNWWNTdDE3SzdxNC1TdGRUYnNmbjFZY0pBdHZIRmFCamlGVnQ1MWUzZmdUNUhhWVZxT1lqX1hGQVJhRlplYm1YcVRJOG5LaTBXdGd1YW52R2ZEYVlZcUYwQ1FNek1Xcl80Y3U3NW5z?oc=5", "source_name": "Latham & Watkins LLP", "published_at": "2021-09-29T07:00:00+00:00", "published_display": "29 Sep 2021 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 74, "total_relevant": 3, "sentiment_summary": {"positive": 0, "negative": 0, "neutral": 3, "score": 50, "total": 3, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 66, "events": [{"event": "general", "label": "Market update", "weight": 1.1, "count": 2}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}], "positive_events": 0, "negative_events": 0}, "market_context": {"has_market_context": true, "latest_close": 1.07, "latest_week": "2026-07-10", "one_week_move": -17.1, "four_week_move": -28.2, "twelve_week_move": -59.6, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -1.213586, "market_dynamics_buy_signal": false, "relative_strength": -56.992694, "fair_value_gap": -52.5, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 36.0277, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-17.1% over one week, -28.2% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 53, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TipRanks", "count": 1}, {"label": "marketscreener.com", "count": 1}, {"label": "Latham & Watkins LLP", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 3}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 2}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "50/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "66/100 classification confidence."}, {"label": "Company focus", "value": "3", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-17.1% over one week, -28.2% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Transcenta Returns Two Lilly-Licensed Compounds in US$4 Million Deal, Retains Blosozumab Rights"}], "updated_at": "2026-07-18T01:14:58.004797+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}